The molecular-targeted therapy in advanced differentiated thyroid cancer
10.3969/j.issn.1007-3969.2016.01.005
- VernacularTitle:晚期分化型甲状腺癌的分子靶向治疗
- Author:
Ye GUO
- Publication Type:Journal Article
- Keywords:
Differentiated thyroid cancer;
Molecular genotype;
Sorafenib;
Lenvatinib
- From:
China Oncology
2016;(1):31-34
- CountryChina
- Language:Chinese
-
Abstract:
Along with the extensive understanding of differentiated thyroid cancer (DTC), its distinct molecular genotype and signaling pathway was revealed, which improved the development of molecular-targeted therapy. Regarding radioactive iodine-refractory DTC, multiple multikinase inhibitors including sorafenib and lenvatinib, which target vascular endothelial growth factor (VEGF) pathway, were proved to be effective. Moreover, selective inhibitors and redifferentiation agents were shown to be promising. In the future, individual genetic testing would provide more speciifc information in directing individualized molecular-targeted therapy.
